Vaxcyte (PCVX) Depreciation & Amortization (CF) (2019 - 2026)

Vaxcyte (PCVX) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) changed 0.3% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $16.4 million (up 82.89% YoY), while the FY2025 annual figure was $16.4 million, up 134.13% from the prior year.
• Depreciation & Amortization (CF) fell to $2.9 million in Q1 2026 per PCVX's latest filing, from $7.5 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $7.5 million in Q4 2025 and bottomed at $582000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $1.9 million across 5 years, with a median of $999000.0 in 2024.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) decreased 7.4% — and 2024, when it jumped 222.52%.
• Vaxcyte's Depreciation & Amortization (CF) stood at $959000.0 in 2022, then retreated by 7.4% to $888000.0 in 2023, then surged by 222.52% to $2.9 million in 2024, then jumped by 161.77% to $7.5 million in 2025, then tumbled by 60.69% to $2.9 million in 2026.
• Business Quant data shows PCVX's Depreciation & Amortization (CF) at $2.9 million in Q1 2026, $7.5 million in Q4 2025, and $3.1 million in Q3 2025.